Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
709 (USA) · Dr. Novak
consented 2013-03-03
AEs
1
Serious
1
Dropout signal
–
Adverse events
moderate
serious
reported
Moderate SYNCOPE — outcome: RECOVERED/RESOLVED; onset 2013-03-07 (study day 5.0); relationship: POSSIBLE; serious criteria: life-threatening
Data queries
No data queries.